Clinical and regulatory implications of KEYNOTE-564 trial of adjuvant pembrolizumab in RCC

Lead study author Dr. Toni K. Choueiri, MD, discusses the clinical and regulatory implications of the phase 3 KEYNOTE-564 trial, which explored pembrolizumab (Keytruda) versus placebo following nephrectomy in patients with clear cell renal cell carcinoma. Results presented at the 2021 ASCO Annual Meeting (LBA5) showed that adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death.

Choueiri is director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, and senior physician at Dana-Farber Cancer Institute, as well as Jerome and Nancy Kohlberg chair and professor of medicine at Harvard Medical School.